Trial updateOphthalmology
Study of ALK-001 on the Progression of Stargardt Disease
Recruiting. Phase 3. Registered enrolment: 230. Alkeus Pharmaceuticals, Inc.
Why it matters
Track this study through NCT07419334. No results are posted in this registry record.
The study at a glance
- Registry status
- Recruiting
- Phase
- Phase 3
- Registered enrolment
- 230
- Results posted
- No
- Sponsor
- Alkeus Pharmaceuticals, Inc.
Keep in mind
Registry information describes the study; recruitment status alone does not establish efficacy or safety.